- NEWPROMRI-PATHWAY – A New Prostate Magnetic Resonance Imaging (MRI) Pathway — Recruiting • Oncology • NCT06672926.
- Prostate cancer is the second most common cancer in men worldwide. The demand for magnetic resonance imaging (MRI) to diagnose and manage prostate cancer is continually growing. There is, however, a severe global shortage of radiologists who review and make decisions on….
- Sponsor: University Hospitals of North Midlands NHS Trust.
Verify eligibility, endpoints and current status on the original source registry before acting on this summary.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
Prostate cancer is the second most common cancer in men worldwide. The demand for magnetic resonance imaging (MRI) to diagnose and manage prostate cancer is continually growing. There is, however, a severe global shortage of radiologists who review and make decisions on prostate scans. This shortage causes compromises that are inefficient and negatively affect care provision, patient outcomes, and patient experiences. Two key examples of these compromises are that every patient receives a gadolinium contrast injection during a prostate MRI scan and patients often require multiple imaging appointments. If radiologists'…
- : * MRI radiographers in University Hospitals of North Midlands (UHNM) and or University Hospitals of Derby and Burton (UHDB) with over 5 years' experience in MRI of the prostate. * Radiographers from UHNM or UHDB who have completed an online and hands on study specific training materials before the testing phase. * Retrospective data of 800 patients each from UHNM and UHDB who have had mpMRI and went on to have a biopsy.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.